论文部分内容阅读
冠状动脉旁路术、冠状动脉造影术及冠状动脉内溶栓疗法的广泛开展已证实血栓是急性透壁性心肌梗塞的直接原因(占70%～80%)。Mandekorn 等进一步指出,在非透壁性心肌梗塞和严重不稳定型心绞痛中,冠脉内血栓亦起主要的病因性作用。Fletcher等于1959年首先采用静脉输注溶栓制剂治疗急性心肌梗塞。1960年 Boyles 等证明,局部使用纤溶制剂(链激酶与纤溶酶之混合物)可迅速溶解犬冠脉实验性血栓。1979年 Ren-trop 等采用冠脉内溶栓法治疗急性心肌梗塞取得了显著效果。大量研究证明,溶栓疗法在挽救濒死心肌、缩小梗塞面积、改善左室功能及降低急性心肌梗塞病死率等方面均有显著疗效,是一种有希望的治疗方法。溶栓药物1.链激酶(Streptokinase):是目前使用
Coronary artery bypass surgery, coronary angiography and coronary thrombolytic therapy has been extensively developed thrombus has been confirmed as a direct cause of acute transmural myocardial infarction (70% to 80%). Mandekorn et al further pointed out that in non-transmural myocardial infarction and severe unstable angina, coronary thrombosis also played a major etiological role. Fletcher equal in 1959, the first intravenous infusion of thrombolytic agents for the treatment of acute myocardial infarction. In 1960 Boyles et al. Demonstrated that topical use of a fibrinolytic agent (a mixture of streptokinase and plasmin) rapidly dissolves experimental coronary thrombosis in dogs. 1979 Ren-trop and other coronary thrombolysis in the treatment of acute myocardial infarction achieved remarkable results. A large number of studies have shown that thrombolytic therapy in the rescue of dying myocardium, infarct size, improve left ventricular function and reduce the mortality of acute myocardial infarction and other aspects have a significant effect, is a promising method of treatment. Thrombolytic drugs 1. Streptokinase: is currently used